Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

Clinical trial NCT05116007 · COMPLETED

Trial details

NCT number: NCT05116007
Sponsor: Akeso
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

SCLC, Extensive Stage

Start date: 2021-03-29
Primary completion: 2023-12-04
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.